Cevimeline

In the US, Cevimeline (cevimeline systemic) is a member of the drug class cholinergic agonists and is used to treat Sjogren's Syndrome.

US matches:

• Cevimeline


• Cevimeline Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N07AX03

CAS registry number (Chemical Abstracts Service)

0107233-08-9

Chemical Formula

C10-H17-N-O-S

Molecular Weight

199

Therapeutic Category

Nootropic

Chemical Names

(+/-)-cis-2-Methylspiro[1,3-oxathiolane-5,3'-quinuclidine] (WHO)

cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)

Spiro(1-azabicyclo(2.2.2)octane-3,5'-(1,3)oxathiolane), 2'-methyl-, hydrochloride, hydrate (2:1), cis-

Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, cis- (USAN)

Foreign Names

• Cevimelinum (Latin)
• Cevimelin (German)
• Céviméline (French)
• Cevimelina (Spanish)

Generic Names

• AF 102F (IS)
• Cevimeline Hydrochloride (OS: USAN)
• AF 102 B (IS)
• Cevimeline hydrochloride hemihydrate (IS: NLM)
• FKS 508 (IS)
• Saligren (IS: NipponKayaku)
• SND 5088 (IS)
• SNI 2011 (IS)
• SNK 508 (IS)

Brand Names

• Evoxac
  Daiichi Sankyo, Japan; Daiichi Sankyo, United States



• Saligren
  Nippon Kayaku, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.